RegulatoryJun 3, 2026, 04:06 PM
Iovance Amtagvi Approved in Australia for Advanced Melanoma
AI Summary
Iovance Biotherapeutics announced that Australia's Therapeutic Goods Administration (TGA) granted conditional approval for Amtagvi (lifileucel) for previously treated advanced melanoma. This marks the company's third marketing authorization for Amtagvi and represents the first T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy. The approval is significant given Australia's high melanoma rates and was based on positive safety and efficacy data from the C-144-01 clinical trial.
Key Highlights
- Amtagvi (lifileucel) received approval with conditions from Australia's Therapeutic Goods Administration (TGA).
- Amtagvi is indicated for adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody.
- This marks Iovance's third marketing authorization for Amtagvi globally.
- Australia has the highest rate of melanoma globally, with an estimated 17,000 new cases and over 1,500 deaths annually.
- Approval was based on safety and efficacy results from the global, multicenter C-144-01 trial.
- Iovance is in the process of authorizing its first Australian treatment center.
- The company is also investigating Amtagvi in frontline advanced melanoma (TILVANCE-301) and other solid tumor types.
Price Impact
More from IOVA